*Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
UK-VNCCLL-220184 | May 2022
UK-VNCCLL-230003. Date of Preparation: March 2023.
Dosing schedules for VENCLYXTO combination regimens
VENCLYXTO combinations are designed to give your CLL patients a chance to take their life back with a fixed treatment duration.1-5
The 5-week dose-titration schedule is designed to gradually reduce tumour burden (debulk) and decrease the risk of TLS. 1
Ven+O: Designed to be completed in 1 year in 1L CLL1
*Each cycle is 28 days.
†Administered orally. Start the 5-week VENCLYXTO dose titration schedule on cycle 1 day 22.
‡100 mg on cycle 1 day 1, followed by 900 mg, which may be administered on day 1 or 2.
IV = intravenous; Ven+O= VENCLYXTO + obinutuzumab.
Ven+R: Designed to be completed in 2 years following the 5 week dose titration in R/R CLL patients1
*Each cycle is 28 days.
†Administered orally.
IV = intravenous; Ven+R = VENCLYXTO + rituximab.
* The modified dose should be continued for 1 week before increasing the dose.
A larger dose reduction may occur at physicians discretion.
Consider discontinuation of VENCLYXTO if patients have to be dose-reduced to less than 100 mg for more than two weeks.
* The modified dose should be continued for 1 week before increasing the dose.
CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.
References
- VENCLYXTO Summary of Product Characteristics.
- Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
- Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
- Leukaemia Care Living with Leukaemia 2018 Report https://media.leukaemiacare.org.uk/wp-content/uploads/Living-with-Leukaemia-2018-Full-Report_compressed.pdf (accessed May 2022).
- Al-Sawaf O et al. Am J Hematol. 2021; 96(9): 1112-19. doi: 10.1002/ajh.26260.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
UK-VNCCLL-220191. Date of preparation: May 2022.
